Top Markets
#1 EXOD EXOD +56.80%
#2 Glidr Glidr +36.41%
#3 Cysic Cysic +25.00%
#4 Velvet Velvet +21.00%
#5 Fabric Protocol Fabric Protocol +18.27%
#6 Bedrock Bedrock +17.29%
#7 Nillion Nillion +16.73%
#8 Nockchain Nockchain +14.69%
#9 Perle Perle +12.86%
#10 Versatize Coin Versatize Coin +12.49%
Coin of the day
EXOD EXOD
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Amniotics AB (publ) Amniotics AB (publ)

Amniotics AB (publ)

AMNI
Rang in Aktien #37511
Amniotics AB (publ) specializes in the creation, manufacturing, and... Amniotics AB (publ) specializes in the creation, manufacturing, and commercialization of stem cell-based therapies, utilizing mesenchymal stem cells to address critical, life-threatening illnesses. The company's primary therapeutic candidate, PulmoStem, is designed for the treatment of inflammatory and fibrotic conditions affecting the lungs. Furthermore, Amniotics is advancing other promising treatments such as CogniStem for neurological disorders, NephroStem for kidney-specific ailments, and CutiStem for various dermatological issues. Beyond its own pipeline, the firm provides contract development and manufacturing services for advanced therapy medicinal products to pharmaceutical companies, universities, and hospitals. Established in 2015, Amniotics AB is headquartered in Lund, Sweden.
Aktienkurs
$0.00060315
Zuletzt synchronisiert: 2024-09-27
Marktkapitalisierung
$1.65M
Veränderung (1 Tag)
19.64%
Veränderung (1 Jahr)
0.00%
Land
SE
Handel Amniotics AB (publ) (AMNI)

Kategorie

Healthcare
P/B-Verhältnis für Amniotics AB (publ) (AMNI)
P/B-Verhältnis zum August 2026 TTM: 0.98
Laut den neuesten Finanzberichten und dem Aktienkurs von Amniotics AB (publ) beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 0.98. Am Ende des Jahres 2022 lag das P/B-Verhältnis bei 43.73.
P/B-Verlauf für Amniotics AB (publ) von 2018 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
2026 (TTM) 0.98 -40.17%
2023 1.63 -96.28%
2022 43.73 263.99%
2021 12.01 -34.02%
2020 18.21 -69.40%
2019 59.51 -75.80%
2018 245.87 0.00%
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/B-Verhältnis P/B-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 550.32%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 540.00%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.4612 254.92%
BE